Predicting hematologic toxicity of lutetium-177 prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer using pretreatment gallium-68 prostate-specific membrane antigen positron emission tomography imaging: preli
Pretreatment PSMA PET imaging may help predict adverse effects in Asian mCRPC patients undergoing Lu-177 PSMA therapy. Larger, prospective studies are needed for confirmation.
Authors
- Pei‐Ing Lee (ORCID: https://orcid.org/0000-0002-8532-7517)
- Yu-Yi Huang (ORCID: https://orcid.org/0000-0003-1259-1840)
- Kuo‐Cheng Huang (ORCID: https://orcid.org/0000-0001-9971-8343)
Institutions
- National Yang Ming Chiao Tung University (TW)
- GTx (United States) (US)
- Koo Foundation Sun Yat-Sen Cancer Center (TW)
Publication Details
- Journal
- Nuclear Medicine Communications
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1097/mnm.0000000000002086
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00